As vaccine development against the novel coronavirus is in full swing , Cuba is testing immunizers at different stages. Havana Laboratories are working with five vaccines, three of which are developed by the Finlay Institute for Vaccines (IFV) and called Soberana 01, Soberana 02 and Soberana Plus, while two more – Abdala and Mambisa – by the Center for Genetic Engineering and biotechnology (CIGB, in the acronym in English).

All Cuban vaccines use the protein antigen of the S coronavirus. But the antigens have a different origin. Thus, Sovereign vaccines use an antigen received from mammalian cells, while Mambisa and Abdala are based on yeast cells.

The Mambisa vaccine is nothing more than a nasal spray that causes systematic, mucosal immunity. This vaccine also contains the hepatitis B virus protein. The advantage of Cuban vaccines is that they can be stored at temperatures of two to eight degrees Celsius.

Sovereign 02
One of the most advanced vaccines among the five developed in Cuba and the first candidate in Latin America to be a drug against Covid-19 is Soberana 02.

On March 3, the National Center for the Control of Drugs, Equipment and Medical Products approved the application of the protocol for the third phase of clinical trials of the vaccine, thus making it possible to vaccinate 44,010 of those tested between 19 and 80 years of age in the United States. United States, controlled clinical trials and providing data on the clinical efficacy of the immunizer.

In addition to those people who participated in the tests, since March 22, the trials include 150,000 volunteers, including health workers.

Vaccination is carried out in a two-dose scheme with an interval of 28 days, but the possibility of receiving a third dose to strengthen immunity is also being explored.

Given the deadlines set for the trials, it is expected that in the second half of 2021, the process of mass vaccination of the population of the island will begin.

IFV is a leading organization in the field of vaccine research, development and manufacture on the island with a professional experience of over 30 years.

The Abdala vaccine project developed by the CIGB also launched the third phase of clinical trials on March 22. This drug will be applied to 48,000 volunteers aged 19 to 80 years according to a vaccination schedule with three doses, one every 14 days.

Soberana 02 and Abdala are both on the list of 23 candidate vaccines against SARS-CoV-2 in the third phase of clinical trials, known around the world. The two Cuban vaccines will be applied in the near future in Venezuela, the center said.

Pharmaceutical company BioCubaFarma has confirmed the operation of six production lines to ensure the production of five Cuban vaccines against Covid-19 and the start of mass vaccination on the island in August this year.

“Having these creation frameworks promises us the portions important to inoculate our populace. By August at the latest, the doses necessary to immunize the entire Cuban population will have been manufactured, ”the company confirmed.

Leave a Reply

Your email address will not be published.